Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights
Provided By GlobeNewswire
Last update: Feb 27, 2025
– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer –
– Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. Phase 1/2 enrollment expected to begin 1H 2025 –
Read more at globenewswire.com
